NOVARTIS PHARMA AG 4
4 · Poseida Therapeutics, Inc. · Filed Jul 16, 2020
Insider Transaction Report
Form 4
NOVARTIS PHARMA AG
10% Owner
Transactions
- Conversion
Common Stock
2020-07-14+5,908,089→ 5,908,089 total - Conversion
Series C Preferred Stock
2020-07-14−7,367,387→ 0 total→ Common Stock (5,908,089 underlying)
Footnotes (2)
- [F1]Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
- [F2]These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities.